Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a One-Time gene fix free thalassemia patients from lifelong transfusions?

NCT ID NCT06364774

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 22 times

Summary

This study tests a new gene therapy for people with a severe blood disorder called beta-thalassemia, who currently need regular blood transfusions. The therapy involves taking the patient's own blood stem cells, adding a healthy gene to help produce normal red blood cells, and returning them to the patient. The goal is to reduce or eliminate the need for transfusions. The study is early-stage (Phase 1/2) and will enroll 12 participants aged 18 to 40.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.